An active component containing pterodontic acid and pterodondiol isolated from Laggera pterodonta inhibits influenza A virus infection through the TLR7/MyD88/TRAF6/NF‑κB signaling pathway

Wang,Yutao; Li,Jing; Yan,Wen; Chen,Qiaolian; Jiang,Zhihong; Zhang,Rongping; Pan,Xiping; Wang,Xinhua

doi:10.3892/mmr.2018.8947

An active component containing pterodontic acid and pterodondiol isolated from Laggera pterodonta inhibits influenza A virus infection through the TLR7/MyD88/TRAF6/NF‑κB signaling pathway

Authors:
- Yutao Wang
- Jing Li
- Wen Yan
- Qiaolian Chen
- Zhihong Jiang
- Rongping Zhang
- Xiping Pan
- Xinhua Wang
View Affiliations

Affiliations: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China, Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, P.R. China, School of Pharmaceutical Science and Biomedical Engineering Research Center, Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, Yunnan 650500, P.R. China, Institute of Chinese Integrative Medicine, Guangzhou Medical University, Guangzhou, Guangdong 511436, P.R. China
Published online on: May 2, 2018 https://doi.org/10.3892/mmr.2018.8947
Pages: 523-531

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The influenza virus is a pathogen that can cause pandemic and epidemic outbreaks, and therefore represents a severe threat to human health. Antiviral drugs have an important role in the prevention and treatment of influenza, although the increasing emergence of drug resistance has given rise to a requirement for the development of novel antiviral drugs. In the present study, an active component (C8) isolated from Laggera pterodonta was evaluated. The nuclear magnetic resonance spectroscopy and mass spectrometry analysis results revealed that two eudesmane‑type sesquiterpene compounds were identified in C8; pterodontic acid and pterodondiol. C8 was demonstrated to have a broad‑spectrum effect against different influenza viruses, including human and avian influenza viruses, with a half maximal inhibitory concentration value of 19.9‑91.4 µg/ml. The antiviral mechanisms of C8 were further clarified. Western blot analysis verified that C8 inhibited Toll‑like receptor 7, myeloid differentiation primary response protein 88 and tumor necrosis factor (TNF) receptor associated factor 6 expression, in addition to p65 phosphorylation, at a concentration of 100 or 150 µg/ml. An indirect immunofluorescence assay demonstrated that C8 may inhibit p65/NF‑κB nuclear translocation. Additionally, C8 prevented an increase in cytokine mRNA expression, including interleukin (IL)‑1β, IL‑6, IL‑8 and C‑C motif chemokine 2 (MCP‑1). Furthermore, the Bio‑Plex assay results indicated that the protein expression of IL‑6, IL‑8, TNF‑α, C‑X‑C motif chemokine 10, MCP‑1 and C‑C motif chemokine 5 was inhibited. These findings suggest that C8 has the potential to be developed into an anti‑inflammatory drug for the prevention and treatment of influenza A virus infection.

View Figures

View References

1	Marois I, Cloutier A, Meunier I, Weingartl HM, Cantin AM and Richter MV: Inhibition of influenza virus replication by targeting broad host cell pathways. PLoS One. 9:e1106312014. View Article : Google Scholar : PubMed/NCBI
2	Saladino R, Barontini M, Crucianelli M, Nencioni L, Sgarbanti R and Palamara AT: Current advances in anti-influenza therapy. Curr Med Chem. 17:2101–2140. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hussain M, Galvin HD, Haw TY, Nutsford AN and Husain M: Drug resistance in influenza a virus: The epidemiology and management. Infect Drug Resist. 10:121–134. 2017. View Article : Google Scholar : PubMed/NCBI
4	De Clercq E: Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 5:1015–1025. 2006. View Article : Google Scholar : PubMed/NCBI
5	Wang X, Jia W, Zhao A and Wang X: Anti-influenza agents from plants and traditional Chinese medicine. Phytother Res. 20:335–341. 2006. View Article : Google Scholar : PubMed/NCBI
6	Wu Y, Zhou C, Li X, Song L, Wu X, Lin W, Chen H, Bai H, Zhao J, Zhang R, et al: Evaluation of antiinflammatory activity of the total flavonoids of Laggera pterodonta on acute and chronic inflammation models. Phytother Res. 20:585–590. 2006. View Article : Google Scholar : PubMed/NCBI
7	Cao C, Liu B, Zeng C, Lu Y, Chen S, Yang L, Li B and Li Y and Li Y: A polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathway. Cancer Cell Int. 14:1372014. View Article : Google Scholar : PubMed/NCBI
8	Shi S, Huang K, Zhang Y, Zhao Y and Du Q: Purification and identification of antiviral components from Laggera pterodonta by high-speed counter-current chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 859:119–124. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wang Y, Zhou B, Lu J, Chen Q, Ti H, Huang W, Li J, Yang Z, Jiang Z and Wang X: Inhibition of influenza virus via a sesquiterpene fraction isolated from Laggera pterodonta by targeting the NF-κB and p38 pathways. BMC Complement Altern Med. 17:252017. View Article : Google Scholar : PubMed/NCBI
10	Li J, Zhou B, Li C, Chen Q, Wang Y, Li Z, Chen T, Yang C, Jiang Z, Zhong N, et al: Lariciresinol-4-O-β-D-glucopyranoside from the root of Isatis indigotica inhibitsinfluenza A virus-induced pro-inflammatory response. J Ethnopharmacol. 174:379–386. 2015. View Article : Google Scholar : PubMed/NCBI
11	Reed LJ and Muench H: A simple method of estimating fifty percent endpoints. Am J Hyg. 27:493–497. 1938.
12	Zu M, Yang F, Zhou W, Liu A, Du G and Zheng L: In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives. Antiviral Res. 94:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
13	Wu W, Li R, Li X, He J, Jiang S, Liu S and Yang J: Quercetin as an antiviral agent inhibits influenza a virus (IAV) entry. Viruses. 8:E62016. View Article : Google Scholar
14	Uetani K, Hiroi M, Meguro T, Ogawa H, Kamisako T, Ohmori Y and Erzurum SC: Influenza A virus abrogates IFN-gamma response in respiratory epithelial cells bydisruption of the Jak/Stat pathway. Eur J Immunol. 38:1559–1573. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, Cheng PL, Yutao W, Zheng J, Yang Z and Zhang F: The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activitythrough the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 17:1302017. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Mok CK, Kang SS, Chan RW, Yue PY, Mak NK, Poon LL, Wong RN, Peiris JS and Chan MC: Anti-inflammatory and antiviral effects of indirubin derivatives ininfluenza A (H5N1) virus infected primary human peripheral blood-derived macrophages and alveolar epithelial cells. Antiviral Res. 106:95–104. 2014. View Article : Google Scholar : PubMed/NCBI
18	Ramirez-Ortiz ZG, Prasad A, Griffith JW, Pendergraft WF III, Cowley GS, Root DE, Tai M, Luster AD, El Khoury J, Hacohen N and Means TK: The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity. Nat Immunol. 16:495–504. 2015. View Article : Google Scholar : PubMed/NCBI
19	O'Neill LA, Golenbock D and Bowie AG: The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol. 13:453–460. 2013. View Article : Google Scholar : PubMed/NCBI
20	Vitiello M and Galdiero M, Finamore E, Galdiero S and Galdiero M: NF-κB as a potential therapeutic target in microbial diseases. Mol Biosyst. 8:1108–1120. 2012. View Article : Google Scholar : PubMed/NCBI
21	Nimmerjahn F, Dudziak D, Dirmeier U, Hobom G, Riedel A, Schlee M, Staudt LM, Rosenwald A, Behrends U, Bornkamm GW and Mautner J: Active NF-kappaB signalling is a prerequisite for influenza virus infection. J Gen Virol. 85:2347–2356. 2004. View Article : Google Scholar : PubMed/NCBI
22	Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR and Ludwig S: Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signaling cascade. Nat Cell Biol. 3:301–305. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wu MS, Yen HR, Chang CW, Peng TY, Hsieh CF, Chen CJ, Lin TY and Horng JT: Mechanism of action of the suppression of influenza virus replication by Ko-Ken Tang through inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway and viral RNP nuclear export. J Ethnopharmacol. 134:614–623. 2011. View Article : Google Scholar : PubMed/NCBI
24	Holzberg M, Boergeling Y, Schräder T, Ludwig S and Ehrhardt C: Vemurafenib limits influenza a virus propagation by targeting multiple signaling pathways. Front Microbiol. 8:24262017. View Article : Google Scholar : PubMed/NCBI
25	König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, et al: Human host factors required for influenza virus replication. Nature. 463:813–817. 2010. View Article : Google Scholar : PubMed/NCBI
26	Watanabe T, Watanabe S and Kawaoka Y: Cellular networks involved in the influenza virus life cycle. Cell Host Microbe. 7:427–439. 2010. View Article : Google Scholar : PubMed/NCBI
27	La Gruta NL, Kedzierska K, Stambas J and Doherty PC: A question of self-preservation: Immunopathology in influenza virus infection. Immunol Cell Biol. 85:85–92. 2007. View Article : Google Scholar : PubMed/NCBI
28	Paquette SG, Banner D, Zhao Z, Fang Y, Huang SS, Leόn AJ, Ng DC, Almansa R, Martin-Loeches I, Ramirez P, et al: Interleukin-6 is a potential piomarker for severe pandemic H1N1 Influenza A infection. PLoS One. 7:e382142012. View Article : Google Scholar : PubMed/NCBI
29	Planz O: Development of cellular signaling pathway inhibitors as new antiviral against influenza. Antiviral Res. 98:457–468. 2013. View Article : Google Scholar : PubMed/NCBI